Status:
TERMINATED
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Prostate Cancer
Bone Metastases
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases
Eligibility Criteria
Inclusion
- Patients with asymptomatic castrate-resistant prostate cancer with bone metastases who have not received any bisphosphonates in the 12 months prior to enrollment
- 18 years old and over
Exclusion
- Plan to be on cytotoxic or biologic therapy during study
- Active dental problems
- Active heart complications
- Active infection
- Patients with moderate to severe swelling due to fluid
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00757757
Start Date
September 1 2008
End Date
August 1 2009
Last Update
December 19 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
NV Cancer Institute
Las Vegas, Nevada, United States, 89135
2
CTRC
San Antonio, Texas, United States, 78229